Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Primary large B-cell lymphoma of the testis, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Radiotherapy to the remaining testicle prevents relapse there and causes permanent infertility and low testosterone. Nobody has tested whether it can be omitted in men who receive modern systemic treatment.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
The best way to protect the brain is not known. IELSG-10 used methotrexate into the spinal fluid; high-dose intravenous methotrexate reaches the brain tissue better and has not been compared against it in a randomised trial.
Survival in this disease did not improve after rituximab came into use in the way it did for lymphoma of the lymph nodes, and the reason is not established.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
WHO-HAEM5 created primary large B-cell lymphoma of immune-privileged sites, covering the central nervous system, the vitreoretina and the testis. The International Consensus Classification judged the grouping premature but recognised testicular lymphoma as an entity closely related to the central nervous system disease.
Rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone for six to eight cycles, methotrexate into the spinal fluid, and radiotherapy to the remaining testicle. In IELSG-10, which treated 53 men this way, five-year progression-free survival was 74 per cent and overall survival 85 per cent at a median follow-up of 65 months; the five-year cumulative incidence of relapse in the central nervous system was 6 per cent and there were no relapses in the irradiated testicle. Grade 3 or 4 neutropenia occurred in 28 per cent and infection in 4 per cent.
Fifty-three men with stage I or II disease treated with rituximab-containing chemotherapy, methotrexate into the spinal fluid and radiotherapy to the remaining testicle: five-year progression-free survival 74 per cent, overall survival 85 per cent, no relapse in the irradiated testicle and a 6 per cent five-year risk of relapse in the central nervous system.
Across 769 men in the SEER registries diagnosed between 1980 and 2005, median overall survival was 4.6 years and disease-specific survival was 71.5 per cent at three years, 62.4 per cent at five and 43.0 per cent at fifteen. Unlike nodal diffuse large B-cell lymphoma, disease-specific survival did not improve after the year 2000, when rituximab came into use.